Role of Amino Acids and Genetic Disorder in Pathogenesis of Heart Failure
NCT03590522 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 50
Last updated 2019-01-09
Summary
Heart failure (HF) is a continuously growing public health problem. The study aim to provide novel insights into the role of amino acids in pathogenesis of heart failure, to obtain a better understanding of cardiac ryanodine Receptor 2 role as an essential player in excitation-contraction coupling in pathogenesis of heart failure and clarify the potential value of these markers as targets for heart failure therapy
Conditions
Interventions
- GENETIC
-
Ryanodine Receptor 2 gene expression
Ryanodine Receptor 2 gene expression will be measured by real time PCR. In addition, amino acids analysis will be measured in plasma by amino acid analyzer.
Sponsors & Collaborators
-
Assiut University
lead OTHER
Eligibility
- Min Age
- 18 Years
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2019-01-17
- Primary Completion
- 2019-03-28
- Completion
- 2019-03-30
More Related Trials
-
Drug-Induced Sudden Death & Ventricular Arrhythmia
NCT00102180 ·Status: COMPLETED
-
Population Pharmacokinetics of Edoxaban in Chinese Patients With Non-Valvular Atrial Fibrillation
NCT05320627 ·Status: COMPLETED ·Phase: PHASE4
-
REGN5381 in Adult Participants With Heart Failure With Reduced Ejection Fraction
NCT06237309 ·Status: TERMINATED ·Phase: PHASE2
-
Benchmarking an Oral Anticoagulant Treatment Rate in Patients With Nonvalvular Atrial Fibrillation
NCT02919982 ·Status: COMPLETED
-
Early rhBNP on Myocardial Work in Patients With STEMI
NCT04157868 ·Status: UNKNOWN ·Phase: PHASE4
-
Risk Analysis of Cardiotoxic Medication Use Due to Sodium Arsenite Chloride Injection
NCT06060132 ·Status: UNKNOWN
-
A Study of ARRY-371797 in Patients With LMNA-Related Dilated Cardiomyopathy
NCT02057341 ·Status: COMPLETED ·Phase: PHASE2
-
The Effect of Early Administration of Dapagliflozin in STEMI Patients With LV Systolic Dysfunction
NCT05045274 ·Status: UNKNOWN ·Phase: NA
-
Effect of Sodium Glucose Co-transporter 2 Inhibitors on Left Atrial Remodeling in Diabetic Patients
NCT07186153 ·Status: NOT_YET_RECRUITING
-
Dapagliflozin Effect on FunctiOnal Mitral Regurgitation and Myocardial Remodeling
NCT05606718 ·Status: UNKNOWN ·Phase: PHASE4
-
Effects of Dapagliflozin on EChOcardiographic Measures of CarDiac StructurE and Function in Patients with CKD
NCT05359263 ·Status: RECRUITING ·Phase: PHASE2
-
Supramaximal Titrated Inhibition of RAAS in Dilated Cardiomyopathy
NCT01917149 ·Status: COMPLETED ·Phase: PHASE4
-
Recombinant BNP on Heart and Renal Function in Acute Heart Failure
NCT01625403 ·Status: UNKNOWN ·Phase: PHASE2
-
Hemodynamic Effects of Rolofylline in the Treatment of Patients With Heart Failure (7418-503)
NCT00729222 ·Status: COMPLETED ·Phase: PHASE2
-
Effectiveness of Oral Anticoagulants in Elderly Patients With Non-Valvular Atrial Fibrillation and Heart Failure
NCT03508271 ·Status: COMPLETED
-
Blockade of the Renin-angiotensin-aldosterone System in Patients With ARVD
NCT03593317 ·Status: RECRUITING ·Phase: PHASE2
-
Renal Hemodynamic Effects of RLX030A in Subjects With Chronic Heart Failure (CHF)
NCT01546532 ·Status: COMPLETED ·Phase: PHASE2
-
Real-world Research : Assessment of Effect of Combination of Drugs in the Treatment of Heart Failure
NCT06158711 ·Status: NOT_YET_RECRUITING
-
Safety and Hemodynamic Effects and Pharmacokinetics of CXL-1020 in Patients With Stable Heart Failure
NCT01092325 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
NORDIC: Nitric Oxide-Derived Oxidants and Regional Endothelial and Diastolic Dysfunction in Dilated Cardiomyopathy
NCT00293137 ·Status: TERMINATED
-
Administration of the SGLT-2 Inhibitor Dapagliflozin in the Patients With Amyloid Cardiomyopathy
NCT05795400 ·Status: COMPLETED ·Phase: NA
-
Survival Study of the Recombinant Human Neuregulin-1β in Subjects With Chronic Heart Failure.
NCT03388593 ·Status: RECRUITING ·Phase: PHASE3
-
Reverse Remodeling Effects of CDR132L in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction and Cardiac Hypertrophy
NCT05953831 ·Status: WITHDRAWN ·Phase: PHASE2
-
Cardiac Hormone Replacement With Brain Natriuretic Peptide (BNP) in Heart Failure
NCT00252187 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
The Prognostic Impact of Using High-dose Hydralazine in Severe Systolic Heart Failure With Hemodynamically Significant Mitral Regurgitation
NCT04217135 ·Status: UNKNOWN ·Phase: PHASE4